Peripartum Cardiomyopathy
On this page
Direct answer
Heart failure arising in the last month of pregnancy or within five months postpartum, with a left ventricular ejection fraction below 45 per cent and no pre-existing cardiac disease or other identifiable cause, defines peripartum cardiomyopathy. Risk factors include multiparity, older maternal age, pre-eclampsia, prolonged tocolysis, malnutrition and African descent, with incidence reported higher in several African and South Asian series than in Western ones; Kerala registry data have contributed notable Indian estimates. Management is standard heart-failure therapy bent around pregnancy and lactation: after delivery, ACE inhibitors, ARNIs, beta-blockers, SGLT2 inhibitors and mineralocorticoid antagonists are all usable; during pregnancy, hydralazine-nitrates, metoprolol and furosemide carry the load. Bromocriptine — built on the 16-kDa prolactin fragment hypothesis — showed promise in early trials (IPAC) but remains investigational rather than standard care. Roughly half of patients recover ejection fraction, and a subsequent pregnancy with persistent EF below 50 per cent carries substantial risk of deterioration.
What you must remember
- The window: last month of pregnancy to five months postpartum — earlier presentation is termed pregnancy-associated cardiomyopathy, a distinction examiners test.
- Diagnostic triad: heart failure symptoms, LVEF below 45 per cent on echo with a dilated left ventricle, and exclusion of other causes (valve disease, anaemia, thyroid disease, peripartum pulmonary embolism).
- Pathobiology: oxidative stress cleaves prolactin into a 16-kDa antiangiogenic fragment that damages the myocardial vasculature — hence the bromocriptine rationale.
- Drug map by phase: pregnancy — furosemide, metoprolol, hydralazine plus nitrates; postpartum — full guideline therapy including ACE inhibitors and ARNIs (enalapril is compatible with breastfeeding); bromocriptine optional/investigational.
- Anticoagulation: strongly consider with LVEF below 35 per cent, given the hypercoagulable puerperium; thrombosis risk is high.
- Recovery: about half normalise ejection fraction within six months; non-recovery, higher parity and lower baseline EF predict persistent dysfunction.
- Next pregnancy risk: recovered EF 50 per cent or above carries moderate risk; persistent EF below 50 per cent carries a real chance of decompensation and death (RISE-PP data) — contraception counselling is part of treatment.
- Delivery: a stable PPCM patient delivers vaginally with caesarean reserved for obstetric or haemodynamic indications.
A typical case, run properly
A 28-year-old para 2 presents three weeks after an uneventful delivery with orthopnoea and swelling; she is tachycardic, has a third sound, raised JVP and basal crackles. Echo shows a dilated left ventricle with EF 28 per cent and moderate mitral regurgitation. Anaemia, thyroid disease and peripartum pulmonary embolism are excluded. She is diuresed intravenously, started on bisoprolol with careful uptitration once congested, and given an ACE inhibitor — she is postpartum, so the pregnancy prohibitions no longer apply — with an SGLT2 inhibitor added and therapeutic anticoagulation for an EF under 35 per cent.
Bromocriptine is discussed honestly: mechanistically attractive, supported by small trials, unproven in large randomised fashion, and it ends lactation. At her six-month review, EF has recovered to 48 per cent. Counselling now decides outcomes: the next pregnancy will be high-risk; a levonorgestrel intrauterine system or progestin implant provides safe, effective spacing (oestrogen-containing contraception is category 3-4 in this setting); and any future pregnancy needs cardiology co-management from the first trimester.
Where students slip
Four errors recur. Applying pregnancy drug rules to a postpartum patient — ACE inhibitors and ARBs are absolutely contraindicated in pregnancy but standard (with enalapril compatible during lactation) after delivery. Missing the diagnostic window and calling late-pregnancy failure "PPCM" when it technically is pregnancy-associated cardiomyopathy. Overstating bromocriptine as proven therapy rather than investigational. And neglecting contraception and future-pregnancy counselling — in Indian practice, where the next pregnancy often follows quickly and returns to the same or a worse ventricle, that conversation is as prognostically important as any prescription.
Frequently asked questions
What is the diagnostic definition of peripartum cardiomyopathy?
Heart failure with LVEF below 45 per cent occurring from the last month of pregnancy to five months postpartum, without pre-existing heart disease or another identifiable cause.
Which drugs are safe during pregnancy versus postpartum?
In pregnancy: furosemide, metoprolol and hydralazine-nitrates; postpartum the full heart-failure armamentarium applies, including ACE inhibitors and ARNIs.
What is the rationale for bromocriptine?
Oxidative stress generates a harmful 16-kDa prolactin fragment; dopamine agonism with bromocriptine suppresses prolactin, and small trials like IPAC support further study, but it is not standard care.
Who needs anticoagulation in PPCM?
Patients with LVEF below about 35 per cent or intracardiac thrombus, given the markedly prothrombotic puerperium.
What is the risk of a subsequent pregnancy?
Related directly to recovered ejection fraction — EF persistently below 50 per cent carries a substantial risk of deterioration or death, while full recovery lowers but does not abolish the risk.